Immunomodulating drugs in Multiple Sclerosis: What kind of administration do MS patients prefer?

Objective: We conducted a survey in an urban Multiple sclerosis (MS) population in Germany due to the lack of information concerning preferences in the administrations of immunomodulating drugs (IMDs). Method: An anonymous standardised questionnaire was sent to 1985 members of the Berlin section of the German Multiple Sclerosis Association. Questions concerned sociodemographic data, MS related topics, therapy, compliance, treatment preferences and therapists. Response rate was 51.1% (n=1015). Results: If efficacy and side effects were similar among the groups, most participants would prefer an oral administration of IMDs in contrast to nasal, intravenous, subcutaneous or intramuscular administration. However, not only the type of administration but also the balance of efficacy and side effects are important, hence when comparing tablets to injections patients would rather choose a tablet which is more effective even if there are more adverse effects. On the other hand, patients would rather choose an injection if it is more efficient assuming equal adverse effects or if it has less side effects assuming equal efficacy. The experience with current medication also seems to influence the preference for an oral administration. Conclusion: Treating MS is a challenge. Cure is not possible, yet disease-modifying drugs are opportunities to positively influence the disease if administered in a constant manner. To achieve this, compliance must be reassured through medicaments that are balanced and advantageous in terms of administration, side effects and efficacy. These findings should be considered when tailoring drugs to MS patients, aiming to improve compliance and outcome in these patients.